Personalized Medical Care & Dedicated International Patient Concierge

4.9 Patient Satisfaction

en-US

Medical Clinic LogoMedical ClinicHome
Book Consultation
Book Consultation
Patient Guide
SpecialtiesServicesDoctorsOffersArticlesBefore & AfterReviewsAbout UsContact Us
Stem Cell & Biologic Regenerative Medicine Explained

Medical Guide

Stem Cell & Biologic Regenerative Medicine Explained

An honest guide to stem cell and biologic regenerative medicine for joints, the cell source types, and the key US regulatory facts, from a Seoul clinic.

Schedule a Consultation

Stem Cell & Biologic Regenerative Medicine Explained

Medically reviewed by Dr. Heejun Kim, Board-Certified Orthopedic Surgeon, Chief Director, Nucellin Orthopedic Clinic

Stem cell and biologic regenerative medicine is one of the most discussed and most misunderstood areas in orthopedics. The language around it is often optimistic, sometimes far beyond what the evidence supports, so the goal of this article is to explain the basics clearly and honestly. It covers what these therapies are, where the cells and biologic materials come from, what the research does and does not show, and, most importantly, the regulatory facts every patient should understand before making a decision. It is written for international patients researching regenerative options at Nucellin Orthopedic Clinic in Seoul.

Here is the essential context, and it deserves emphasis: stem cell and biologic therapies for orthopedic and joint use are not FDA-approved in the United States; they are considered investigational. The U.S. Food and Drug Administration has issued consumer warnings about unapproved stem cell products, noting real safety risks, including infections and other serious adverse events, associated with some products marketed directly to patients. Care at Nucellin Orthopedic Clinic is delivered in the Republic of Korea under Korean medical regulation, not under U.S. regulation. The evidence base for these therapies in orthopedics is limited and still emerging, no efficacy is guaranteed, and results vary between individuals. This article does not claim that these therapies regrow cartilage, cure arthritis, or allow anyone to avoid surgery.

What "Regenerative Medicine" Means

Regenerative medicine is a broad term for approaches that aim to support or influence the body's own repair processes rather than simply managing symptoms. In orthopedics, this umbrella includes biologic materials such as platelet-rich plasma, and it includes stem cell and cell-based approaches. The shared idea is that biological signals, cells, growth factors, and the environment around them, might be harnessed to support tissue in ways that traditional drugs do not.

It is important to separate the appeal of that idea from the state of the proof. A concept being biologically plausible, and even promising in laboratory or early clinical studies, is not the same as a treatment being proven, standardized, or approved for a specific condition. Honest care keeps those questions distinct. Throughout this article, the emphasis is on education about how these approaches are described and sourced, not on promises about what they can achieve.

What Stem Cells Are

Stem cells are cells that have the potential to develop into other cell types and to support tissue maintenance. In adults, the cells most often discussed in orthopedic contexts are sometimes called mesenchymal stem cells or, more precisely in current scientific usage, mesenchymal stromal cells. These cells are found in various tissues throughout the body. The theory behind using them in orthopedics is that they may help modulate inflammation and support the local tissue environment.

Two points deserve honesty here. First, the science of exactly how these cells behave once delivered into a joint is still being worked out; much of what is claimed in marketing outpaces what is established in rigorous research. Second, the number and quality of cells in a given preparation can vary widely depending on the source, the person, and the processing method, which is one reason study results are so difficult to compare. Understanding the source types below helps explain why.

Source Type 1: Blood-Derived Biologics

The most familiar blood-derived biologic is platelet-rich plasma, or PRP, which is prepared from a small sample of your own blood. It is not, strictly speaking, a stem cell product; it concentrates platelets and their growth factors rather than stem cells. It is included here because it is the entry point many patients encounter within the regenerative umbrella and because it illustrates the key concept of an autologous biologic, one derived from your own body.

Because blood-derived biologics come from the patient, they avoid concerns about rejection or donor material. As with all the sources discussed here, however, "autologous" describes where the material comes from, not whether it works for a particular condition. In the United States, PRP as a therapy is not FDA-approved for orthopedic use and is considered investigational; the kits and centrifuges used to prepare it may be cleared as devices, but that is a separate matter from approval of the therapy itself.

Source Type 2: Bone Marrow-Derived Cells

Bone marrow is a well-known reservoir of cells and is one of the classic sources in cell-based orthopedics. In practice, a sample of bone marrow is typically drawn, often from the pelvis, and processed to concentrate its cellular components. The resulting preparation is frequently referred to as bone marrow aspirate concentrate. It contains a mixture of cells and growth factors, and the population of true stem or stromal cells within it is generally small.

The rationale for using bone marrow-derived preparations in joints is that they may deliver cells and signals thought to support the tissue environment. The honest regulatory picture is that these preparations are not FDA-approved for orthopedic or joint indications in the United States and remain investigational. The aspiration procedure itself carries considerations such as discomfort at the harvest site, and, as with any procedure, potential risks that should be discussed with a physician. Evidence for meaningful, durable benefit in joint conditions is limited and still developing.

Source Type 3: Adipose (Fat)-Derived Cells

Adipose tissue, ordinary body fat, is another source that has attracted considerable interest because it is relatively accessible and contains cells of interest. Fat is typically obtained through a small procedure similar in principle to liposuction, and it is then processed to isolate the cellular fraction. Adipose-derived preparations are often promoted because fat is abundant and the harvest is comparatively straightforward.

Here the regulatory nuance is especially important. In the United States, how adipose tissue is processed can determine whether the FDA considers the result to be a minimally manipulated tissue or a drug requiring approval; many adipose stem cell products marketed for orthopedic use fall into the category of unapproved products, and the FDA has specifically warned about such products. In short, adipose-derived cell therapy for joints is investigational and not FDA-approved. As with the other sources, benefit is not guaranteed, evidence is limited, and processing methods vary, which complicates any comparison across clinics or studies.

The Regulatory Reality You Must Understand

This section is the one to read twice. Across all three source types, the same core facts apply in the United States: these stem cell and biologic therapies are not FDA-approved for orthopedic or joint indications, they are investigational, and the FDA has warned consumers about unapproved stem cell products because of documented safety risks. Those risks have included serious infections and other adverse events linked to some products. A clinic being able to offer a therapy does not mean that therapy is proven or approved.

At Nucellin Orthopedic Clinic, these services are provided in the Republic of Korea under Korean medical regulation, which is a different legal and regulatory framework from that of the United States. Disclosing this is not a formality; it is central to informed decision-making for international patients. Wherever you consider such care, it is reasonable and wise to ask what is actually known about the therapy for your specific condition, what the risks are, how the material is sourced and processed, and what realistic expectations should be. Any source that promises to regrow cartilage, cure arthritis, or guarantee that you can avoid surgery is overstating what is known.

What the Evidence Does and Does Not Show

The scientific literature on stem cell and biologic therapies in orthopedics is active and growing, and some early studies report improvements in pain or function for certain conditions. That is why the field remains a serious area of research. But the evidence as a whole is limited and emerging: many studies are small, use different cell sources and processing methods, have short follow-up, and vary in quality, which makes firm conclusions difficult. Because preparations are not standardized, two patients described as receiving "stem cell therapy" may in fact receive very different products.

The honest summary is that these therapies may be of interest to appropriately selected and fully informed patients, that the evidence remains limited and still developing, and that no result can be guaranteed. Equally important is what the evidence does not support: it does not establish that these therapies reliably regrow cartilage, reverse or cure arthritis, or serve as a proven substitute for surgery. Keeping expectations grounded in what is actually known is part of responsible care.

A Conservative-First Approach

For most joint and musculoskeletal conditions, a conservative-first approach is sensible. Activity modification, physical therapy, weight management where relevant, and time are reasonable starting points, and they often help. Established treatments, when needed, have the benefit of clearer evidence and regulatory standing. Investigational biologic options are best considered thoughtfully, as one possibility among several, after conservative measures have been given a fair chance and after an honest discussion of the limits of the evidence.

Non-surgical and regenerative approaches do not guarantee that surgery can be avoided, and framing them that way is misleading. Imaging such as X-ray, ultrasound, or MRI is a diagnostic tool that helps clarify the problem; it is not a treatment. The value of a careful diagnosis is that it matches any intervention to the right patient and the right problem, rather than applying the same option to everyone.

Who Might Be a Candidate

Candidacy for any biologic or cell-based approach is decided by examination, not by a website or a symptom checklist. A physician will review your history, examine the affected joint, and consider appropriate imaging before discussing whether an option is reasonable for you. Part of that discussion should include your overall health, the severity and nature of your condition, the realistic likelihood of benefit, the known risks, and the regulatory status of the therapy.

Being fully informed is essential precisely because these therapies are investigational. A responsible consultation will explain uncertainties openly rather than making promises. If you ever feel that a provider is guaranteeing outcomes or using cure-oriented language, that is a reason for caution, not reassurance.

Cost and Insurance Context

This article does not discuss prices. It is worth knowing, however, that regenerative and investigational orthopedic treatments are typically not covered by U.S. health insurance, since they are generally considered elective and not established for these indications. Coverage rules differ by plan and by country, so confirm the specifics with your own insurer and directly with the clinic.

About the Clinic and the Reviewing Physician

Nucellin Orthopedic Clinic is located at 4F, 71 Dokseodang-ro, Yongsan-gu, Seoul, Republic of Korea, and is a Registered Medical Institution for Attracting Foreign Patients, certified by the Korean Ministry of Health and Welfare. The clinic offers adipose-derived and bone marrow-derived stem cell services among its regenerative options, and an English-speaking coordinator supports inquiries and interprets during consultations. The clinic's philosophy emphasizes addressing the underlying biological causes of musculoskeletal problems, not only symptoms.

This article was medically reviewed by Dr. Heejun Kim, the clinic's Chief Director and a board-certified orthopedic surgeon (a Korean credential). His background includes training at Yonsei University College of Medicine and an orthopedic surgery residency at Severance Hospital, along with roles as a Clinical Instructor and a Clinical Professorship at the Artificial Joint Center at Severance. He is a regular member of multiple Korean and international societies, including the International Society for Medical Shockwave Treatment (ISMST). To ask about your own situation, visit the clinic website or the contact page.

Frequently Asked Questions

Are stem cell therapies FDA-approved for joints or arthritis?

No. In the United States, stem cell and biologic therapies for orthopedic and joint indications are not FDA-approved and are considered investigational. The FDA has also warned consumers about unapproved stem cell products because of documented safety risks. At Nucellin Orthopedic Clinic, these services are provided under Korean medical regulation.

What are the main sources of cells and biologics?

The three sources discussed here are blood-derived biologics such as platelet-rich plasma, bone marrow-derived cells (often prepared as a concentrate from a marrow sample), and adipose (fat)-derived cells obtained through a small harvest. Each is autologous, meaning it comes from your own body, and each varies in how it is processed. "Autologous" describes the source, not whether the therapy is proven for a given condition.

Can stem cell therapy regrow cartilage or cure my arthritis?

No. The current evidence does not establish that these therapies reliably regrow cartilage or reverse or cure arthritis, and they should not be described that way. They may be of interest to fully informed patients in some situations, but results vary, the evidence is limited and emerging, and no outcome is guaranteed.

Will stem cell therapy let me avoid surgery?

There is no guarantee of that. Regenerative and investigational approaches do not reliably prevent the need for surgery, and framing them as a way to avoid surgery is misleading. Whether any option is appropriate depends on your diagnosis and a careful discussion with a physician.

Are these therapies safe?

Because most orthopedic biologics are autologous, they avoid concerns about donor material, but that does not make them proven or free of risk. The FDA has warned about serious adverse events, including infections, linked to some unapproved stem cell products, and harvesting procedures carry their own considerations. Safety and effectiveness are separate questions and should both be discussed with a physician.

How do I know if I am a candidate?

Candidacy is decided by examination, not by an online checklist. A physician reviews your history, examines the affected area, and considers appropriate imaging, then discusses realistic expectations, risks, and the investigational status of any option. A responsible consultation explains uncertainty openly rather than promising results.

The Bottom Line

  • Stem cell and biologic regenerative medicine in orthopedics uses materials from three main autologous sources: blood, bone marrow, and adipose (fat) tissue.
  • In the United States, these therapies are not FDA-approved for joint or orthopedic use; they are investigational, and the FDA has warned about unapproved stem cell products and their safety risks.
  • The evidence is limited and still emerging; some early studies are encouraging, but results vary and no benefit can be guaranteed.
  • These therapies do not reliably regrow cartilage, cure arthritis, or allow patients to avoid surgery, and should not be described that way.
  • Care at Nucellin Orthopedic Clinic is delivered under Korean regulation; candidacy is decided by examination, and a conservative-first approach is sensible.

Disclaimer

This article is for general educational purposes only and is not a self-diagnosis tool. It does not replace an in-person consultation, examination, or personalized advice from a qualified physician. Stem cell and biologic therapies for orthopedic use are not FDA-approved in the United States and are considered investigational; the FDA has warned about unapproved stem cell products. Care at Nucellin Orthopedic Clinic is delivered in the Republic of Korea under Korean medical regulation, not under U.S. regulation. No specific result is guaranteed, and individual outcomes vary. Always seek the advice of a qualified health provider with any questions about a medical condition.

More Articles

Continue reading our clinical guides.

View All

Learn More

Learn More

Medical Clinic

Dedicated to evidence-based medical care, personalized treatment planning, and comprehensive support for local and international patients.

Treatments

SpecialtiesServicesMedical TeamSpecial OffersMedical Articles

Patient Guide

About UsHow It WorksBefore & AfterPatient ReviewsPress & Media

Information & Legal

Contact & LocationSite SearchPrivacy PolicyRefund & Cancellation PolicyTerms of Use

© Medical Clinic. All rights reserved.

Individual clinical results may vary. Please consult a board-certified specialist.